Valbenazine
Valbenazine is a highly selective vesicular monoamine transporter 2 (VMAT2) inhibitor that depletes monoamines (particularly dopamine) from presynaptic nerve terminals by blocking their re-uptake into synaptic vesicles, reducing dopaminergic activity in striatal pathways. It is approved for the treatment of tardive dyskinesia (TD), an involuntary movement disorder caused by prolonged dopamine receptor antagonist therapy. Its VMAT2 selectivity reduces off-target effects compared to older VMAT inhibitors like tetrabenazine.
Berat Molekul
418,6000 g/mol
LogP
4,30
TPSA
74,00 Ų
Lipinski RO5
Lulus
Area Terapeutik
Mekanisme Kerja
Competitively binds to its target receptor without activating it, blocking the natural ligand from binding and preventing receptor-mediated signaling.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Competitively binds to its target receptor without activating it, blocking the natural ligand from binding and preventing receptor-mediated signaling.
Struktur 2D
Cite this structure
Embed this structure
SMILES
COc1cc2c(cc1OC)[C@H]1C[C@@H](OC(=O)[C@@H](N)C(C)C)[C@H](CC(C)C)CN1CC2
InChI
InChI=1S/C24H38N2O4/c1-14(2)9-17-13-26-8-7-16-10-21(28-5)22(29-6)11-18(16)19(26)12-20(17)30-24(27)23(25)15(3)4/h10-11,14-15,17,19-20,23H,7-9,12-13,25H2,1-6H3/t17-,19-,20-,23+/m1/s1
Molecular Formula
C24H38N2O4
HBD / HBA
1 / 6
Ikatan yang Dapat Dirotasi
8
Atom Berat
30
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Pertanyaan yang Sering Diajukan
Valbenazine is a highly selective vesicular monoamine transporter 2 (VMAT2) inhibitor that depletes monoamines (particularly dopamine) from presynaptic nerve terminals by blocking their re-uptake into synaptic vesicles, reducing dopaminergic activity in striatal pathways. It is approved for the treatment of tardive dyskinesia (TD), an involuntary movement disorder caused by prolonged dopamine receptor antagonist therapy. Its VMAT2 selectivity reduces off-target effects compared to older VMAT inhibitors like tetrabenazine.
Competitively binds to its target receptor without activating it, blocking the natural ligand from binding and preventing receptor-mediated signaling.
Yes, Valbenazine is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL2364639. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 24795069. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="valbenazine"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/valbenazine/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/valbenazine/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/valbenazine/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="valbenazine"></drugfyi-drug>